Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review concluded that FDA-cleared low-level laser therapy devices are safe and effective for patients with male and female pattern hair loss who do not respond to or tolerate standard treatments.

This study found that combining low-fluence Q-switched Nd: YAG laser and intense pulsed light led to faster and more effective melasma treatment compared to using the laser alone, though recurrence still occurred.

This study found that low-fluence 1064 nm Q-switched Nd:YAG laser treatment effectively improved melasma in Asian patients without serious side effects, achieving an average improvement rate of 50-74%.

This study evaluated the effectiveness and safety of low-dose oral minoxidil (2.5-5 mg daily) in men with male androgenetic alopecia, aiming to contribute data to an area with limited previous reports. Results are not provided in the abstract.

This review found that low-level laser therapy appears promising in improving hair regrowth and patient satisfaction in androgenetic alopecia, though results should be interpreted cautiously.

This review discusses low-level light therapy for androgenetic alopecia and female pattern hair loss, noting minimal clinical evidence on its efficacy and the need for more controlled studies.

In a 24-week randomized trial, this study found that the RAMACAP laser helmet significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, although limitations included a small sample size and potential issues with the control used.

This study found that low-level laser therapy may improve hair growth in patients with androgenetic alopecia, either as a standalone treatment or combined with minoxidil or finasteride, without reported adverse reactions.

In a rat model of chemotherapy-induced alopecia, this study found that low-level laser treatment significantly accelerated hair regrowth without affecting the efficacy of chemotherapy.

This study found that a low estrogen-containing oral contraceptive normalized hormone levels and improved symptoms in women with polycystic ovary disease, with minimal side effects reported.

This study found that low-level laser therapy may significantly improve androgenic alopecia in both men and women, either alone or alongside treatments like minoxidil and finasteride.

This study found that women experiencing diffuse hair loss had significantly lower levels of plasma sex-hormone binding globulin compared to controls, while their testosterone levels remained normal.

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

This case series reported that low-dose naltrexone may benefit patients with lichen planopilaris by reducing scalp symptoms and slowing disease progression, with no adverse effects observed in the patients.

This study found that combining low-level light therapy with topical minoxidil 5% may lead to better hair regrowth and patient satisfaction in treating female pattern hair loss compared to using each treatment alone.

This review suggested that low-level light therapy using red/near-infrared light could be a safe and effective treatment for various skin and hair conditions, though more robust trials are needed to solidify its clinical utility.

In this clinical study, low-level laser therapy using the HANDI-DOME LASER device increased hair counts by 51% compared to controls, indicating its potential as a safe and effective treatment for androgenetic alopecia in women aged 18 to 60.

This review discusses the current evidence and highlights gaps in research needed for the wider acceptance of low-level laser therapy as a treatment for hair loss; no new clinical results are provided.

In this randomized, double-blind trial, researchers observed that low-level laser therapy led to significantly greater hair regrowth on treated areas compared to a sham treatment in patients with androgenetic alopecia over 24 weeks, suggesting it as a potentially effective and safe option.

This case report identified UVB photosensitivity and testicular failure as previously unreported components of low-sulfur hair syndrome in a 16-year-old male.

This review discusses the differential diagnosis of low-renin hypertension and highlights recent genetic discoveries related to familial forms, but it presents no new clinical results.

This study found that low iron stores are a risk factor for excessive hair loss in non-menopausal women.

In this study, low grade inflammation was associated with skin conditions like atopic eczema, onychomycosis, and rosacea in an adult Finnish population.

This study found that a lower maintenance dose of flutamide (125 mg/day) effectively maintained the reduction in hirsutism achieved with an initial higher dose (250 mg/day) in women, without additional side effects.

This review concludes that current clinical and preclinical evidence does not indicate oncologic safety concerns linked to photobiomodulation therapy for skin rejuvenation, including no clear evidence of increased cancer risk.

This review highlights the possible role of T regulatory cells in the immune-related mechanisms of alopecia areata but reports no new clinical findings.

This study found that low-level laser therapy may have promising effects on hair regrowth in dogs with noninflammatory alopecia, with most animals showing improvement after treatment.

This review found that low-level laser therapy significantly increased hair density in adults with androgenic alopecia compared to sham treatments, with greater effects observed at lower treatment frequencies.

This review discusses the mixed evidence and high risk of bias in studies on low-level light therapy for treating androgenetic alopecia and calls for rigorous randomized controlled trials to assess its efficacy.

This study found that combining micro-needling, low-level laser therapy, and autologous non-activated platelet-rich plasma increased hair density in patients with androgenic alopecia over the treatment period.